The following table presents the calculation of basic and diluted net income per share (in thousands, except per share information):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2015		2014		2015		2014
Net income	$	3,997	$	6,387	$	8,063	$	9,433
Basic:
Weighted-average shares of common stock outstanding		33,333		31,564		33,190		31,147
Shares used in computing basic net income per share		33,333		31,564		33,190		31,147
Effect of dilutive securities:
Stock options		-		96		1		113
Restricted stock subject to vesting		354		485		429		592
Contingently issuable shares (1)		-		38		-		19
Shares issuable for acquisition consideration (2)		451		1,088		531		1,078
Shares used in computing diluted net income per share		34,138		33,271		34,151		32,949

Basic net income per share	$	0.12	$	0.20	$	0.24	$	0.30
Diluted net income per share	$	0.12	$	0.19	$	0.24	$	0.29

Anti-dilutive options and restricted stock not included in the calculation of diluted net income per share		-		290		54		145

(1)	For the three and six months ended June 30, 2014, this represents the Company's estimate of shares to be issued to Clear Task, Inc. ("Clear Task") pursuant to the Asset Purchase Agreement.

(2)

For the three and six months ended June 30, 2015, this represents the shares held in escrow pursuant to: (i) the Agreement and Plan of Merger with ForwardThink Group Inc. ("ForwardThink"); (ii) the Asset Purchase Agreement with BioPharm Systems, Inc. ("BioPharm"); (iii) the Asset Purchase Agreement with Trifecta Technologies, Inc. and Trifecta Technologies Canada, Limited (together "Trifecta"); and (iv) the Asset Purchase Agreement with Zeon (as defined below) as part of the consideration. For the three and six months ended June 30, 2014, this represents the shares held in escrow pursuant to: (i) the Agreement and Plan of Merger with Northridge Systems, Inc.; (ii) the Agreement and Plan of Merger with TriTek Solutions, Inc.; (iii) the Asset Purchase Agreement with Clear Task; (iv) the Asset Purchase Agreement with CoreMatrix Systems, LLC; (v) the Agreement and Plan of Merger with ForwardThink; (vi) the Asset Purchase Agreement with BioPharm; and (vii) the Asset Purchase Agreement with Trifecta as part of the consideration.